AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Anti-Progesterone in Breast Cancer Chemoprevention

Technology Application: Treatment of BRCA1 mediated breast cancer

Detailed Technology Description: Treatment with anti-progesterone, mifepristone, prevents tumorigenesis in mice carrying mutated Brca1/p53 alleles. Anti-progesterone pellet containing 30mg/60 days constant release mifepristone (RU486), or placebo pellet was implanted into twelve 3- and two 4- month-old mice. Mice were monitored weekly for tumor formation. All control mice or placebo pellet treated mice developed palpable tumors. In the RU486 treated group no palpable tumors were detected.The invention is published in Science 1 December 2006 314: 1467-1470

Application No.: 9517240

Others: Tech ID/UC Case
18780/2006-560-0

Related Cases
2006-560-0

*Abstract: BRCA1 is a breast cancer susceptibility gene. According to estimates of lifetime risk, 36 to 85 percent of women with an altered BRCA1 or BRCA2 gene will develop breast cancer.

*IP Issue Date: Dec 13, 2016

*Principal Investigator: Name: Yoon Kim
Department:

Name: Eva Y H P Lee
Department:

Name: Ying Li
Department:

Name: Aleksandra Poole
Department:

Country/Region: USA

For more information, please click Here